Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal microbiota transplantation (FMT) is a live biotherapeutic product being investigated by the Air Force Military Medical University (also known as Fourth Military Medical University) in China for the treatment of refractory IgA nephropathy (IgAN). The intervention consists of live intestinal microbiota from healthy donors, administered to patients via methods such as transendoscopic enteral tubing (TET), retention enema, or enteric microbial capsules. [12, 15, 16] The therapeutic goal is to restore gut microecological balance and modulate the gut-kidney axis, as gut dysbiosis is believed to contribute to the pathogenesis of IgAN. [14, 16] A prospective cohort study (NCT03633864) and early case reports have shown that FMT can reduce 24-hour urinary protein levels and increase serum albumin while being generally well-tolerated. [12, 14, 16]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fecal microbiota transplantation (Air Force Medical University).